Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies.

mAbs - 1 Jan 2024

Tsai Wen-Ting K, Li Yinyin, Yin Zhaojun, Tran Peter, Phung Qui, Zhou Zhenru, Peng Kun, Qin Dan, Tam Sien, Spiess Christoph, Brumm Jochen, Wong Manda, Ye Zhengmao, Wu Patrick, Cohen Sivan, Carter Paul J

Abstract excerpt

Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG for clinical development. For example, we have extensively used knobs-into-holes (KIH) mutations to facilitate the heterodimerization of antibody heavy chains and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATR gene

Share to Immunoglobulin G

Share to Mutation

Share to Risk Assessment

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38845069
DOI: 10.1080/19420862.2024.2362789
PMCID: PMC11164226

Genes

ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies.PMID 38845069Read ↗

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read ↗

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesSemantic proximity Read ↗

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cellsSemantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.Semantic proximity Read ↗

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approachesSemantic proximity Read ↗

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface.Semantic proximity Read ↗

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.Semantic proximity Read ↗

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read ↗

Statistical Methodology for Qualification of a Non-Clinical Risk Assessment Peptide:T Cell Proliferation Assay to Support Decision MakingSemantic proximity Read ↗

Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics with a Bell-Shaped Efficacy CurveSemantic proximity Read ↗

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.